Internal Medicine, Rheumatology · Shreveport, LA
NPI
1013132653
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8508 Line Ave Ste C
Shreveport, LA, 71106
Phone (318) 219-7704
Groups this clinician bills Medicare through
Medicare paid, 2024
$282K
16,673 services
Medicare patients, 2024
568
Average age 72
Drug cost, 2024
$7.1M
3,477 prescriptions
Company payments, 2025
$1,611
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kyla Lokitz was code J0897 (injection, denosumab, 1 mg), 5,400 times for 50 patients. In total Kyla Lokitz billed 16,673 services in 19 codes, and Medicare paid $282K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,400 | 50 | $20.31 | $110K |
| 99214 Office E&M - Established | Office | 1,172 | 508 | $85.64 | $100K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 938 | 498 | $12.20 | $11K |
| 96401 Chemotherapy Administration | Office | 152 | 60 | $45.76 | $6,956 |
| 99204 Office E&M - New | Office | 111 | 111 | $118.34 | $13K |
By year: 2022 $289K for 22,206 services; 2023 $392K for 37,516 services; 2024 $282K for 16,673 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kyla Lokitz prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 756 prescriptions and refills. In total Kyla Lokitz wrote 3,477 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 756 | 1,618 | 221 | $20K |
| Hydroxychloroquine Sulfate Generic | 471 | 1,203 | 154 | $23K |
| Humira(Cf) Pen Adalimumab | 229 | 230 | 27 | $1.7M |
| Duloxetine Hcl Generic | 207 | 535 | 56 | $3,433 |
| Allopurinol Generic | 184 | 473 | 56 | $2,841 |
| Leflunomide Generic | 160 | 430 | 56 | $10K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 136 | 136 | 21 | $1.1M |
| Prednisone Generic | 135 | 210 | 51 | $860 |
| Enbrel Mini Etanercept | 128 | 128 | 17 | $952K |
| Gabapentin Generic | 85 | 213 | 30 | $1,012 |
| Mycophenolate Mofetil Generic | 70 | 145 | 22 | $8,427 |
| Forteo Teriparatide | 68 | 70 | 11 | $301K |
| Alendronate Sodium Generic | 68 | 189 | 28 | $726 |
| Sulfasalazine Generic | 67 | 181 | 24 | $1,837 |
| Azathioprine Generic | 54 | 114 | 18 | $2,739 |
Brand drugs: 1,167 claims; generic drugs: 2,297 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kyla Lokitz $1,611 ($1,611 in general payments such as food, travel and fees) from 7 companies. The largest payer was Abbvie Inc. with $491.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.